In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

I agree with @Dr. @Dr. First Last's previous answer (posted July 2020). In addition, the 2024 ACR Lupus Nephritis guidelines (discussed at the 2024 ACR meeting) still recommend mycophenolate (MMF) or cyclophosphamide as first-line induction therapies for lupus nephritis (LN), rather than B-cell depl...

B-cell directed therapies with or without a standard of care (SoC) are not regarded as first-line therapies for lupus nephritis. Following the case series of successful treatments of lupus nephritis with rituximab, the LUNAR study showed that rituximab+SoC improved immunologic parameters but not cli...